Quetiapine for the treatment of bipolar mania in older adults

摘要: Objectives:  A post hoc analysis of pooled data from two quetiapine monotherapy clinical trials was conducted to evaluate the efficacy and tolerability therapy (twice daily, 400–800 mg/day) among bipolar manic adults aged 55 years older. The primary endpoint change baseline in Young Mania Rating Scale (YMRS) total score at Day 21. secondary YMRS 84. Methods:  407 patients made up safety population, consisting 59 older (aged ≥55 years) 348 younger adults. 403 344 Efficacy outcomes were analyzed using covariance models (ANCOVA); descriptive statistics are presented for outcomes. Results:  Both individuals treated with had significant improvement on scores compared placebo-treated patients. adult group demonstrated a sustained reduction placebo that apparent by 4 treatment. For treatment groups, most common adverse effects (at frequency ≥10%) dry mouth, somnolence, postural hypotension, insomnia, weight gain, dizziness adults, insomnia event both adults. Conclusions:  This suggests represents potentially useful option I mania. Studies focus geriatric mania, including larger patient numbers, needed confirm these findings.